Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection
Primary Purpose
Hepatic Insufficiency, Liver Failure
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Preoperative glucose infusion
Preoperative normal saline infusion
Sponsored by
About this trial
This is an interventional prevention trial for Hepatic Insufficiency focused on measuring Glucose infusion, Liver function, Liver resection, Albumin synthesis, Stable isotopes
Eligibility Criteria
Inclusion Criteria:
- American Society of Anesthesiologists class ≤3
- liver resection (one or more liver segments) for primary or secondary malignancy
- ability to give informed consent
Exclusion Criteria:
- signs of severe malnutrition or obesity: body mass index (BMI) <20 or >30 kg.m-2, more than 10% involuntary body weight loss over the preceding six months, serum albumin <35 g.L-1
- chronic viral liver disease
- diabetes mellitus
- significant cardiorespiratory, renal and neurological disease
- musculoskeletal or neuromuscular disease
- severe anemia (hemoglobin <10 g.dL-1)
- history of severe sciatica or back surgery or other conditions which contraindicate the use of an epidural catheter
Sites / Locations
- Royal Victoria Hospital, McGill University Health CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
Glucose infusion.
Normal saline infusion.
Outcomes
Primary Outcome Measures
Rate of albumin synthesis
Secondary Outcome Measures
Transthyretin synthesis, fibrinogen synthesis, whole body glucose and protein kinetics
Full Information
NCT ID
NCT00623662
First Posted
February 15, 2008
Last Updated
April 2, 2018
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
1. Study Identification
Unique Protocol Identification Number
NCT00623662
Brief Title
Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection
Official Title
Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Unknown status
Study Start Date
February 2008 (undefined)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
March 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of the study is to determine whether intravenous glucose administration before liver resection preserves hepatic glycogen resulting in improved hepatic metabolic function after the operation.
We further investigate whether the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection.
Detailed Description
Background. With a reported incidence of up to 70%, liver failure is the most frequent complication necessitating intensive care and prolonging hospital stay. Animal studies suggest that the glycogen content of the liver is a key regulator of liver function and that glycogen depletion, a mandatory consequence of preoperative fasting, is associated with poor clinical outcome.
The results of a pilot study demonstrate that metabolic preconditioning, i.e. the avoidance of preoperative fasting by intravenous administration of dextrose preserves hepatic glycogen and prevents hepatic dysfunction after liver resection. Liver function in this protocol was assessed by a score originally proposed by Schindl including serum concentrations of total bilirubin and lactate, prothrombin time and degree of encephalopathy. Due to alterations induced by anesthesia and surgery, e.g. blood loss necessitating transfusion, hypothermia, inflammatory responses and use of drugs with impact on hepatobiliary metabolism, liver function scores do not necessarily reflect functional integrity and metabolic capacity of the liver. In contrast, measuring the production of proteins that are exclusively synthetized by hepatocytes such as albumin allows a more specific and quantitative assessment of hepatic performance under perioperative conditions.
Hypothesis. We propose a randomized double-blinded study to test the hypothesis that, in patients scheduled for resection of liver cancer, metabolic preconditioning with intravenous dextrose preserves hepatic glycogen resulting in improved hepatic metabolic function postoperatively. We further hypothesize that the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection. Hepatic synthetic capacity will be assessed by measuring albumin synthesis using a stable isotope tracer technique.
Research plan. In order to test the validity of our assumptions, we will perform studies in patients scheduled for minor (study I; one or two liver segments, n=30) or major (study II; three or more liver segments, n=20) liver resection. In a double blinded fashion patients will be randomly assigned to receive either intravenous dextrose at 2 mg/kg/min or saline from 15:00 on the day before the operation until surgical skin incision. Metabolic processes at the organ level (liver, muscle), i.e. fractional synthesis rates of albumin, hepatic acute phase proteins (transthyretin (=prealbumin), fibrinogen, total plasma proteins) and muscle protein will be determined one day before and one day after the operation using primed-continuous infusions of L-[2H5]phenylalanine. Stable isotopes (L-[1-13C]leucine, [6,6-2H2]glucose) will be applied to assess dynamic changes in whole body protein and glucose metabolism before and after surgery, i.e. protein breakdown, amino acid oxidation, protein synthesis, glucose production and glucose uptake.
Significance. The demonstration that the preconditioning with dextrose preserves metabolic performance of the liver would have important implications for the clinical management of surgical patients with liver cancer. If preoperative dextrose administration attenuates hepatic dysfunction after liver resection, it will provide these patients with a readily available, safe and inexpensive therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Insufficiency, Liver Failure
Keywords
Glucose infusion, Liver function, Liver resection, Albumin synthesis, Stable isotopes
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Glucose infusion.
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Normal saline infusion.
Intervention Type
Other
Intervention Name(s)
Preoperative glucose infusion
Intervention Description
Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
Intervention Type
Other
Intervention Name(s)
Preoperative normal saline infusion
Intervention Description
Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
Primary Outcome Measure Information:
Title
Rate of albumin synthesis
Time Frame
One day before and one day after surgery
Secondary Outcome Measure Information:
Title
Transthyretin synthesis, fibrinogen synthesis, whole body glucose and protein kinetics
Time Frame
One day before and one day after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists class ≤3
liver resection (one or more liver segments) for primary or secondary malignancy
ability to give informed consent
Exclusion Criteria:
signs of severe malnutrition or obesity: body mass index (BMI) <20 or >30 kg.m-2, more than 10% involuntary body weight loss over the preceding six months, serum albumin <35 g.L-1
chronic viral liver disease
diabetes mellitus
significant cardiorespiratory, renal and neurological disease
musculoskeletal or neuromuscular disease
severe anemia (hemoglobin <10 g.dL-1)
history of severe sciatica or back surgery or other conditions which contraindicate the use of an epidural catheter
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ralph Lattermann, MD PhD
Phone
514-934-1934
Ext
35802
Email
ralph.lattermann@muhc.mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Schricker, MD PhD
Phone
514-934-1934
Ext
36057
Email
thomas.schricker@mcgill.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ralph Lattermann, MD PhD
Organizational Affiliation
Department of Anaesthesia, McGill University Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Victoria Hospital, McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralph Lattermann, MD PhD
Phone
514-934-1934
Ext
35802
Email
ralph.lattermann@muhc.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Thomas Schricker, MD PhD
Phone
514-934-1934
Ext
36057
Email
thomas.schricker@mcgill.ca
First Name & Middle Initial & Last Name & Degree
Ralph Lattermann, MD PhD
First Name & Middle Initial & Last Name & Degree
Thomas Schricker, MD PhD
First Name & Middle Initial & Last Name & Degree
George Carvalho, MD MSc
First Name & Middle Initial & Last Name & Degree
Peter Metrakos, MD
First Name & Middle Initial & Last Name & Degree
Linda Wykes, PhD
First Name & Middle Initial & Last Name & Degree
Mazen Hassanain, MD
12. IPD Sharing Statement
Learn more about this trial
Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection
We'll reach out to this number within 24 hrs